Abstract
Patient-derived tumor xenograft (PDTX) mouse models were used to discover new therapies for naïve and drug resistant BRAFV600E-mutant melanoma. Tumor histology, oncogenic protein expression, and antitumor activity were comparable between patient and PDTX-matched models thereby validating PDTXs as predictive preclinical models of therapeutic response in patients. PDTX models responsive and non-responsive to BRAF/MEK standard of care (SOC) therapy were used to identify efficacious combination therapies. One such combination includes a CDK4/6 inhibitor that blocks cell cycle progression. The rationale for this is that the retinoblastoma protein (pRb) is 95% wildtype in BRAF mutant melanoma. We discovered that 77/77 stage IV metastatic melanoma tissues were positive for inactive phosphorylated pRb (pRb-Ser780). Rb is hyperphosphorylated and inactivated by CDK4/6:cyclin D1 and when restored to its hypophosphorylated active form blocks cell cycle progression. The addition of a CDK4/6 inhibitor to SOC therapy was superior to SOC. Importantly, triple therapy in an upfront treatment and salvage therapy setting provided sustained durable response. We also showed that CDK4/6 blockade resensitized drug resistant melanoma to SOC therapy. Durable response was associated with sustained suppression of pRb-Ser780. Thus, reactivation of pRb may prove to be a clinical biomarker of response and the mechanism responsible for durable response. In light of recent clinical trial data using this triple therapy against BRAFV600E-mutant melanoma, our findings demonstrating superior and prolonged durable response in PDTX models portend use of this therapeutic strategy against naïve and SOC resistant BRAF V600E-mutant metastatic melanoma coupled with pRB-Ser780 as a biomarker of response.
Highlights
Metastatic melanoma is a disease with poor prognosis [1], primarily due to its complex tumor heterogeneity, distinct profiles of somatic mutations involved in tumorigenesis [2], and intrinsic resistance to both chemotherapy and radiotherapy [3]
The aberrant activation of ERK and inactivation of pRb contribute to constitutive oncogenic signaling within tumor cells, which has been previously reported in BRAFV600E-mutant melanoma [25, 26].To confirm the aberrant expression of these two pathways, we examined clinical samples using a tissue microarrays (TMAs) of human stage IV melanoma tissues for pERK and pRB-Ser780
Mice were treated until study completion with indicated dosing and schedules. a, po, oral gavage; qd, everyday this, we investigated the antitumor activity of palbociclib in combination with dual dabrafenib and trametinib treatment (DT) as an upfront triple therapy combination and palbociclib as a salvage therapeutic strategy added to dual standard of care (SOC) treatment when tumors escape dual BRAF/ MEK inhibition
Summary
Metastatic melanoma is a disease with poor prognosis [1], primarily due to its complex tumor heterogeneity, distinct profiles of somatic mutations involved in tumorigenesis [2], and intrinsic resistance to both chemotherapy and radiotherapy [3]. Single agent BRAF inhibition has increased overall survival (OS) by 20% [6] and immune therapies, such as ipilimumab, have increased OS by 32%, with response rates varying between 32-45% [7, 8] Despite these improvements, varying mechanisms of resistance occur in patients. Immune therapies are associated with innate resistance, whereas targeted therapies are associated with acquired resistance [9], which the latter is often associated with reactivation of the MAPK pathway which promotes cell proliferation, drug resistance and protection from apoptosis [10] This underscores the need to identify new therapies that improve disease management and patient survival that suppress cell cycle progression, prevent or reverse drug resistance and promote cell death
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have